Overview

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)